ClinicalTrials.gg
RecruitingNCT07480824Updated Apr 6, 2026

To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Hepatic Impairment Subjects

A Phase 1 interventional study of TQ05105 in Myelofibrosis, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Primary Myelofibrosis by Sino Biopharmaceutical Limited — 3 open to participants now, 5 under way, none of them phase 3. Primary Myelofibrosis · Sino Biopharmaceutical Limited.

Planned enrollment
6th of 10
24 · median 28
Started
2026
with 3 others
Phase 1
7 of 10
1 open now
Registered
7th of 10
by date

Among the 10 studies in Primary Myelofibrosis by Sino Biopharmaceutical Limited, this one is the 6th largest by planned enrollment, is one of 4 that started in 2026, is one of 7 in phase 1, and was the 7th registered.

Primary Myelofibrosis

627 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

3 of the 10 studies in Primary Myelofibrosis by Sino Biopharmaceutical Limited are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Primary Myelofibrosis by Sino Biopharmaceutical Limited, or all of them as a file.
02

Study summary

This is an open, open-label, parallel, single-dose, phase I clinical study designed to evaluate the pharmacokinetic (PK) profile of TQ05105 tablet in patients with hepatic impairment after a single dose, and to evaluate the safety of the drug in these patients after a single dose.

03

Conditions studied

  • Myelofibrosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntarily participate in the clinical trial and sign the form, with full understanding of the trial content, procedures, and potential adverse reactions.
  • Patients (including partners) have no pregnancy plans or sperm/egg donation plans from screening until 6 months after the last dose of the drug, and agree to use effective .
  • Aged 18-75 years (inclusive), regardless of gender.
  • Male participants weigh ≥50.0 kg; female participants weigh ≥45.0 kg. (BMI) = weight (kg)/height² (m²), with BMI ranging 18.0-32.0 kg/m² (inclusive).
  • Patients can communicate effectively with investigators and comply with the trial protocol.

Additional Criteria for Participants with Normal Liver Function:

  • Negative serum and Virus (HCV) antibody test results.
  • Weight within ±10 kg of the average weight of groups A/B; age within ±10 years of the average age of groups A/B; gender distribution similar to groups A/B (±1 participant per gender).

Additional Criteria for Participants with Impaired Liver Function:

  • Chronic liver injury caused by primary liver diseases (e.g., hepatitis B/C, non-alcoholic fatty liver disease, alcoholic liver disease) or clinically diagnosed cirrhosis, classified as Grade A or B.
  • Stable condition within 2 weeks prior to dosing as judged by the investigator.
  • No medication within 4 weeks before screening, or stable treatment regimen for underlying diseases (including liver-protective therapy).

Exclusion criteria

Exclusion Criteria:

  • History or current diagnosis of severe/chronic diseases (e.g., digestive, respiratory, neurological, cardiovascular, hematological, endocrine, oncological, immunological, or psychiatric disorders) deemed unsuitable by the investigator (except primary liver diseases and complications in participants with impaired liver function).
  • Conditions affecting drug absorption, distribution, metabolism, or excretion (e.g., dysphagia) or prior gastrointestinal resection impacting these processes.
  • Use of strong/moderate , CYP2C9, or CYP2C19 inducers/inhibitors within 4 weeks before screening.
  • Known to TQ05105 tablet components or allergic constitution (e.g., allergy to ≥2 substances, drug allergy history, or prone to rash/eczema/asthma).
  • Average daily smoking >5 cigarettes within 3 months before screening.
  • Drug abuse history or positive urine drug screen within 3 months.
  • For alcoholic liver disease participants: history of excessive drinking (>2 alcohol units/day) within 1 year; for others: such history within 3 months.
  • Blood donation/loss ≥200 mL or plasmapheresis within 4 weeks before screening.
  • Consumption of alcohol (or positive breath test), grapefruit juice, coffee, tea, cola, or chocolate within 48 hours before dosing.
  • (CLcr) \<60 mL/min.
  • Pregnant/lactating women, positive pregnancy test, or unprotected sex within 2 weeks before screening.
  • Positive antibody or Treponema pallidum-specific antibody.
  • Other factors deemed unsuitable by the investigator.

Additional Exclusions for Normal Liver Function Participants:

  • Use of prescription/non-prescription drugs, herbal medicines, or supplements (e.g., vitamins) within 2 weeks before screening.
  • The results of physical examination during the screening period, vital signs, clinical laboratory tests (blood cell analysis (five categories), blood biochemistry, coagulation function, urine routine examination with sediment), , frontal and lateral chest X-rays, abdominal ultrasound (liver, gallbladder, pancreas, spleen), and urinary system ultrasound, etc., which showed abnormal results and were determined by the research doctor to have clinical significance.
  • Patients in other drug trials within 3 months or 5 half-lives (whichever longer) before screening.

Additional Exclusions for Impaired Liver Function Participants:

  • Had a history of liver transplantation;
  • Patients with hepatic coma within 30 days before screening;
  • Patients who had used drugs that might cause acute hepatotoxicity (such as halothane and methotrexate) within 3 months before screening;
  • Patients with acute liver disease caused by drug or viral infection within 2 months before screening;
  • With biliary cirrhosis, liver/bile duct obstruction, cholestatic liver disease and other diseases affecting biliary excretion;
  • Patients with liver failure or liver cancer, or patients with a history of esophagogastric variceal bleeding, hepatic encephalopathy, severe portal hypertension, or a portasystemic shunt within 1 year before screening who were judged by the investigator to be ineligible for the trial;
  • Patients with abnormal physical examination, vital signs, clinical laboratory tests (blood cell analysis (five classification), blood biochemistry, coagulation function, urine routine and sediment), AFP, electrocardiogram, chest X-ray, echocardiography, abdominal ultrasound (liver, gallbladder, pancreas and spleen), urinary ultrasound, and routine electroencephalogram (EEG) during the screening period and judged by the research doctors as not suitable for the study;
  • Patients with massive ascites on ultrasound during the screening period who were assessed by the investigators as not suitable for the trial;
  • Who participated in and used any drug within 1 month before screening.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Active comparator
    A: Mild hepatic impairment (Child-Pugh A)

    A: 15 mg orally , single dose

    Drug: TQ05105

  • Active comparator
    B: Moderate hepatic impairment (Child-Pugh B)

    B: 10 mg orally , single dose

    Drug: TQ05105

  • Active comparator
    C: Normal

    C: 15 mg orally , single dose

    Drug: TQ05105

Interventions

  • Janus Kinase Inhibitors/Rho-associated Kinase (JAK/ROCK) inhibitors

06

What researchers measure

Primary outcomes

  1. Peak concentration (Cmax)

    Maximum plasma drug concentration of TQ05105 and TQ12550

    Time frame: Before administration, 10, 20, 30, 45 minuets,1, 2, 3, 4, 6, 8, 12, 24, 48 hours after administration

  2. Area under the concentration-time curve (AUC)

    Area under the plasma concentration-time curve of TQ05105 and TQ12550

    Time frame: Before administration, 10, 20, 30, 45 minuets,1, 2, 3, 4, 6, 8, 12, 24, 48 hours after administration

Secondary outcomes

  1. Time-to-maximum concentration( Tmax) of TQ05105 and TQ12550

    Time-to-maximum concentration

    Time frame: Before administration, 10, 20, 30, 45 minuets,1, 2, 3, 4, 6, 8, 12, 24, 48 hours after administration

  2. Plasma half life (t1/2)

    The time it takes for the concentration or amount in the body of that drug to be reduced by exactly one-half of TQ05105 and TQ12550

    Time frame: Before administration, 10, 20, 30, 45 minuets,1, 2, 3, 4, 6, 8, 12, 24, 48hours after administration

  3. Apparent volume of distribution (Vz/F)

    Apparent Volume of Distribution at the Terminal Phase divided by Bioavailability

    Time frame: Before administration, 10, 20, 30, 45 minuets,1, 2, 3, 4, 6, 8, 12, 24, 48hours after administration

  4. Terminal elimination rate (λz)

    First-order rate constant associated with the terminal (log-linear) elimination phase of TQ05105 and TQ12550

    Time frame: Before administration, 10, 20, 30, 45 minuets,1, 2, 3, 4, 6, 8, 12, 24 hours after administration

  5. Curve extrapolated to infinity (AUC_%Extrap)

    Percentage of the Area Under the Curve extrapolated to infinity

    Time frame: Before administration, 10, 20, 30, 45 minuets,1, 2, 3, 4, 6, 8, 12, 24 hours after administration

  6. Apparent Clearance (CL/F)

    The apparent volume of plasma from which the drug is completely removed per unit time, adjusted for bioavailability

    Time frame: Before administration, 10, 20, 30, 45 minuets,1, 2, 3, 4, 6, 8, 12, 24 hours after administration

  7. Fraction unbound(fu%)

    The proportion of a drug or substance in the bloodstream that is not bound to plasma proteins and is therefore free to exert pharmacological activity, be metabolized, or undergo elimination.

    Time frame: 0.5, 2, 6 hours after administration

  8. Adverse event rate

    The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs).

    Time frame: Baseline up to day7

07

Study locations

1 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Oct 2026, 6 months after the start.

Of 68 phase 1 interventional studies under Primary Myelofibrosis, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 103. This study's planned 6 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2026
First posted
Mar 18, 2026
StartActual
Apr 1, 2026
Primary completionEst.
Oct 2026
CompletionEst.
Dec 2026
Last update
Apr 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07480824
Responsible party
Sponsor
First posted
Mar 18, 2026
Start date
Apr 1, 2026
Primary completion
Oct 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Apr 6, 2026

Study contacts

Wei Zhao, Doctor
Contact
zhao4wei2@hotmail.com
0531-85875449

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: JAK2 Inhibitor TQ05105

Start the discussion